Endothelial deletion of PKCδ prevents VEGF inhibition and restores blood flow reperfusion in diabetic ischemic limb

Laura Croteau1*, Clément Mercier1*, Étienne Fafard-Couture1, Alexandre Nadeau1, Stéphanie Robillard1, Valérie Breton1, Andréanne Guay1, Farah Lizotte1, Marc-Antoine Despatis2 and Pedro Geraldes1,3

Abstract

Aims: Peripheral artery disease is a complication of diabetes leading to critical hindlimb ischemia. Diabetes-induced inhibition of VEGF actions is associated with the activation of protein kinase Cδ (PKCδ). We aim to specifically investigate the role of PKCδ in endothelial cell (EC) function and VEGF signaling.

Methods: Nondiabetic and diabetic mice, with (ec-Prkcd−/−) or without (ec-Prkcdf/f) endothelial deletion of PKCδ, underwent femoral artery ligation. Blood flow reperfusion was assessed up to 4 weeks post-surgery. Capillary density, EC apoptosis and VEGF signaling were evaluated in the ischemic muscle. Src homology region 2 domain-containing phosphatase-1 (SHP-1) phosphatase activity was assessed in vitro using primary ECs.

Results: Ischemic muscle of diabetic ec-Prkcdf/f mice exhibited reduced blood flow reperfusion and capillary density while apoptosis increased as compared to nondiabetic ec-Prkcdf/f mice. In contrast, blood flow reperfusion and capillary density were significantly improved in diabetic ec-Prkcd−/− mice. VEGF signaling pathway was restored in diabetic ec-Prkcd−/− mice. The deletion of PKCδ in ECs prevented diabetes-induced VEGF unresponsiveness through a reduction of SHP-1 phosphatase activity.

Conclusions: Our data provide new highlights in mechanisms by which PKCδ activation in EC contributed to poor collateral vessel formation, thus, offering novel therapeutic targets to improve angiogenesis in the diabetic limb.

Keywords

Diabetes, peripheral arterial disease, PKCδ, vascular endothelial growth factor, SH2 domain-containing phosphatase 1

Key messages

- Endothelial deletion of PKCδ improve blood flow reperfusion in diabetic limb
- VEGF signaling is restored by the endothelial ablation of PKCδ
- PKCδ increase SHP-1 expression in endothelial cells of diabetic limb
- SHP-1 phosphatase activity is blunted in PKCδ-KO primary endothelial cells

Introduction

Peripheral artery disease is a direct manifestation of obstructive atherosclerosis characterized by the progressive narrowing of the artery, which gradually reduces blood supply to the limbs causing critical ischemia.1 Diabetes increases the incidence of PAD and causes 10–16 times higher risk of non-traumatic lower limb amputation, mainly due to insufficient collateral vessel formation.2 Hyperglycemia has been shown to alter angiogenic processes involving complex interplays between various growth factors and cell types.3

1Research Center of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
2Department of Surgery of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
3Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, QC, Canada

*These authors contributed equally to this work.

Corresponding author:
Pedro Geraldes, Department of Medicine, Division of Endocrinology, Université de Sherbrooke, 3001 12e Ave Nord, Sherbrooke, QC J1H 5N4, Canada.
Email: Pedro.Geraldes@USherbrooke.ca
Vascular endothelial growth factor (VEGF) plays a fundamental role in the angiogenic process. VEGF-induced stimulation of VEGF receptor 2 (VEGFR2) triggers the activation of downstream pathways that are involved in the migration and proliferation of endothelial cells (EC). Exogenous local injection of VEGF has been shown to improve neo-vascularization in both mice and humans in a nondiabetic state. However, local administration of VEGF by gene therapy in diabetic individuals did not appear to have the beneficial effects seen in the absence of diabetes. Decreased expression of VEGF was observed in the muscle of diabetic mice and correlated with impairment of VEGF signaling in hyperglycemia. These studies emphasized that impaired vessel formation following ischemia in a diabetic state can be partially attributed to both lack of production and unresponsiveness to critical growth factors including VEGF. Thus, the identification of the underlying molecular mechanisms involved in the deregulation of VEGF signaling in hyperglycemia has generated further interest.

Protein kinase C (PKC) has been identified as a major player in the pathophysiology of diabetic vascular complications. Hyperglycemia-induced activation of the PKCβ isoform contributed to the increase in EC adhesion molecule expression, which caused advanced development of atherosclerotic plaques in ApoE−/− mice. Diabetes contributes to endothelial dysfunction by reducing the expression of endothelial nitric oxide synthase (eNOS) and thereby nitric oxide, an effect that can be prevented by the inhibition of PKC activity. Using a model of critical limb ischemia, we have reported that the PKCδ isoform was upregulated in muscle of diabetic mice. However, the precise contribution of PKCδ activation to EC dysfunction in diabetes and ischemia has never been fully investigated. Given the pivotal role of EC in angiogenesis, the present study investigated the role of PKCδ specifically in EC on blood flow reperfusion and vascular density in a context of hindlimb ischemia. We hypothesized that the endothelial deletion of PKCδ could restore VEGF signaling and promote collateral vessel formation to subsequently improve blood flow reperfusion in the ischemic diabetic limb.

Materials and methods

Reagents and antibodies

Primary antibodies for immunoblotting were purchased from commercial sources: actin (horseradish peroxidase (HRP); I-19), GAPDH-HRP (V18), SHP-1 (C19), VEGF (147), PDGFB (N30) PLCγ (B10) and endothelial nitric oxide synthase (eNOS) 3 (C-20) from Santa Cruz Biotechnology Inc (Dallas, TX); protein kinase B (Akt), phosho-Akt (S473) (D9E), phosho-VEGFR2 (Y1175), VEGFR2, phosho-eNOS (S1177), phosho-SRC (Y416), SRC, phosho-PLCγ (Y783) and secondary antibody of -rabbit and -mouse peroxidase-conjugated from Cell Signaling (Danver, MA); anti-α smooth muscle actin from Abcam (Toronto, ON) and anti-CD31 and collagen type 1 for cell culture were purchased from BD Bioscience (Mississauga, ON). Secondary antibodies for immunofluorescence Alexa-488 conjugated anti-rabbit IgG and Alexa-594 conjugated anti-rat were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Fetal bovine serum (FBS), phosphate-buffered saline (PBS), penicillin-streptomycin (P/S), Dynabead sheep anti-rat and Dulbecco's Modified Eagle Medium (DMEM) low glucose (31600-034) were obtained from Invitrogen (Burlington, ON). VEGF-A165 was purchased from R&D (Minneapolis, MN), Collagenase type 1 was purchased from Worthington Biochemical Corporation (Lakewood, NJ). Endothelial cell growth supplement (ECGS) was purchased from Sciences Cells Research Laboratories. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Animal and experimental design

Specific deletion of PKCδ in EC was generated by breeding Prkdδfl/fl mice14 with the VEC-CRE (B6;129-Tg(Cdh5-cre)1Spe/J) mice from Jackson laboratories (JAX stock #017968). Animals were rendered diabetic for a 2-month period by intraperitoneal streptozotocin injection (50 mg/kg in 0.05 mol/L citrate buffer, pH 4.5; Sigma) on five consecutive days after overnight fasting; control mice were injected with citrate buffer. Blood glucose was measured by Glucometer (Contour, Bayer Inc.). Throughout the study period, animals were provided with free access to water and standard rodent chow (Harlan Teklad, Madison, WI). All experiments were conducted in accordance with the Canadian Council of Animal Care and University of Sherbrooke guidelines.

Hindlimb ischemia model

We have assessed blood flow in nondiabetic (NDM) and 4-month-old diabetic mice (DM), with deletant ec-Prkcd−/− or without (ec-Prkcd+/+) specific deletion of PKCδ in ECs. Animals were anesthetized by inhalation of Isoflurane USP (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) at a concentration of 5% (initiation) and then maintained at 1%–2% during the whole surgical procedure (approximately 20 min). The entire lower extremity of each mouse was shaved. A small incision was made along the thigh all the way to the inguinal ligament and extending superiorly towards the mouse abdomen. Femoral artery was isolated and ligated distally to the origin of the artery profunda femoris as previously described.13
Laser doppler perfusion imaging

Hindlimb blood flow was measured using a laser Doppler perfusion imaging (PIMIII) system (Perimed Inc) as previously described.\(^9\) Consecutive perfusion measurements were obtained by scanning the region of interest (hindlimb and foot) of anesthetized animals. Measurements were performed pre- and post-surgery to ensure the correct ligation, and additionally on postoperative days 7, 14, 21, and 28. To overcome the variables affecting blood flow temporally, results at any given time were expressed as a ratio of simultaneously obtained perfusion measurements of the right (ligated) versus the left (non-ligated) limb.

Histology

Right and left adductor muscles from NDM; DM; ec-Prkcd\(^{5}\) and ec-Prkcd\(^{-/-}\)mice were harvested for pathological examination and sections were fixed in 4% paraformaldehyde (Sigma) for 18 h and then transferred to 70% ethanol for light microscopy.

Immunofluorescence and TUNEL assay

Cross-sections of adductor muscles of each group were blocked and then exposed overnight with primary antibodies (CD31 (1:50) and α-smooth muscle actin, 1:200), followed by 1h incubation with the secondary antibody (1:400). Apoptotic cells were detected using the TACS 2 Tdt-Fluor in situ apoptosis detection kit (Trevigen, Gaithersburg, MD), according to the manufacturer’s instructions with some modifications as we previously described.\(^9\) Images were taken with the Nikon eclipse Ti microscope. Three cross-sections, 50 µm apart, were taken per animal and all images were captured under identical settings and handled in Adobe Photoshop similarly across all images.

Immunoblot analysis

Adductors muscles were lysed in RIPA buffer containing protease inhibitors.\(^9,13\) Protein quantity was measured with DC kit (BioRad). The lysates (20–50 µg protein) were separated by SDS-PAGE. Primary antibodies were incubated overnight at 1:1000 in 5% skim milk or 1:500 in 5% BSA for phospho-VEGFR2 and phospho-eNOS. Antigens were detected using anti-rabbit HRP-conjugated antibody 1:10 000 (or 1:2000 for phospho-VEGFR and phospho-eNOS) and detected with the either ECL system (Pierce Thermo Fisher, Piscataway, NJ) or Luminaforte western HRP substrate (Millipore, Etobicoke, ON). Protein content quantification was performed using computer-assisted densitometry with ImageLab imaging software (Chemidoc, BioRad).

Quantitative PCR analysis

Quantitative PCR was performed to evaluate mRNA expressions of VEGF-A, KDR/Flk-1, eNOS, PDFG and PDGFR-β of the ischemic adductor muscle of all groups as we previously described.\(^13\) PCR primers are listed in Supplemental Table 1. GAPDH expression was used for normalization.

Cell culture

Pulmonary EC were extracted from the lungs of each group of mice. Lungs were sliced into 1-2 mm pieces and incubated at 37°C for 1 h in 0.2% collagenase type 1. The tissue was disrupted by pipetting and passed through a 40 µm cell strainer. Following centrifugation, the pellet was resuspended in 1 ml DMEM/0.1% BSA and incubated with CD31-conjugated Dynabeads for 30 min at 4°C. Beads were wash with DMEM/0.1% BSA using a magnetic support and resuspended in growth medium (DMEM 10% FBS, 1% P/S, ECGS 50 µg/ml and heparin 1 mg/ml). Cells were plated in 100 mm petri dishes coated with type 1 collagen (0.1 mg/ml in 0.02 N acetic acid) and cultured in DMEM with normal (NG; 5.6 mmol/L + 19.4 mmol/L mannitol, NDM) or high (HG; 25 mmol/L, DM) glucose concentrations for 24 h. Cells were then stimulated or not with VEGF-A (10 ng/ml) for 10 min to assess Akt activation. Due to the limited amount of EC collected per mouse, bovine aortic EC (BAEC) were carefully isolated from aorta and alternatively used for phosphatase assays as previously described.\(^9\)

Adenoviral infections

Adenoviral vectors containing green fluorescent protein (GFP) and dominant negative form of PKCδ (Ad-dnPKCδ) or SHP-1 (Ad-dnSHP-1) were used to infect BAEC as we previously reported in retinal pericytes.\(^15\) BAEC were infected with adenoviral vectors at a multiplicity of infection of 100 for 48 h at 37°C.

Phosphatase assay

SHP-1 was immunoprecipitated from cell lysates in buffer without phosphatase inhibitors as previously described.\(^9\) The tyrosine phosphatase assay system (V2471, Promega, Madison, WI) was used to assess phosphatase activity according to the manufacturer’s instructions.

Statistical analyses

The in vivo and ex vivo data were shown as mean ± SD for each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Tukey’s test correction for multiple comparisons. Data in each group
were checked for normal distribution using D’Agostino and Pearson normality test based on $\alpha=0.05$. All results were considered statistically significant at $p < 0.05$.

Results

Specific deletion of PKC$\delta$ in EC improved blood flow reperfusion and vascular density in the diabetic muscle

Nondiabetic and diabetic ec-Prkcd$^{+/+}$ and ec-Prkcd$^{-/-}$ mice underwent unilateral femoral artery ligation. Body weight and fasting blood glucose levels were measured at euthanasia and the deletion of PKC$\delta$ did not affect both parameters in the context of diabetes (Supplemental Table 2). Blood flow reperfusion was assessed using the laser Doppler imaging system (Figure 1(a)). As expected, results showed a 47% decrease of blood flow reperfusion in diabetic ec-Prkcd$^{+/+}$ (41% blood flow recovery) as compared to nondiabetic ec-Prkcd$^{+/+}$ mice (78% blood flow recovery; $p=0.0009$). The specific deletion of PKC$\delta$ in EC significantly improved blood flow reperfusion in the ischemic limb of diabetic ec-Prkcd$^{-/-}$ mice as compared to diabetic ec-Prkcd$^{+/+}$ mice ($p=0.0089$) (Figure 1(b)). Importantly, diabetic ec-Prkcd$^{+/+}$ mice displayed a significant 37.5% reduction of vascular density ($p=0.0314$) as compared to nondiabetic ec-Prkcd$^{+/+}$ mice, suggesting impaired collateral vessel formation (Figure 1(c) and (d)). In contrast, enhanced blood flow reperfusion observed in diabetic ec-Prkcd$^{-/-}$ mice was associated with a 50% increase in vascular density ($p=0.0087$) as compared to diabetic ec-Prkcd$^{+/+}$ mice.

PKC$\delta$ deletion preserved muscle integrity and prevented EC apoptosis in the ischemic diabetic limb

Muscle integrity was significantly ($p < 0.0001$) altered in diabetic ec-Prkcd$^{+/+}$ mice as compared to nondiabetic ec-Prkcd$^{+/+}$ mice, which was characterized by the reduction of the inter-fiber area (Figure 2(a) and (b)). Histological observations showed complete preservation of the muscle integrity and structure 28 days post-ligation in diabetic ec-Prkcd$^{-/-}$ mice, which displayed similar muscle fiber organization as nondiabetic ec-Prkcd$^{+/+}$ mice (Figure 2(a) and (b)). Another potential mechanism that could explain poor
blood flow reperfusion in diabetic mice might be due to early vascular cell apoptosis during ischemia. Therefore, we have quantified the number of positive apoptotic-CD31 co-stained cells in the ischemic muscle of each group (Figure 2(c) and (d)). The percentage of positive apoptotic EC was significantly increased \((p = 0.0009)\) in diabetic ec-Prkcd\(^{ff}\) mice as compared to nondiabetic ec-Prkcd\(^{ff}\) mice. Interestingly, the deletion of PKC\(\delta\) in diabetic mice greatly reduced the percentage of apoptotic cells to similar levels as nondiabetic ec-Prkcd\(^{ff}\) mice.

Inhibition of PKC\(\delta\) specifically in EC restored VEGFR2 but not PDGFR-\(\beta\) expression

We have demonstrated that whole body PKC\(\delta\) knockout mice prevented diabetes-induced inhibition of VEGF and PDGF expression.\(^{13}\) Since several cell types in the muscle can participate in the angiogenic response, we have investigated the endothelial PKC\(\delta\) contribution to the expression of pro-angiogenic factors. Both VEGF-A and PDGF-B mRNA expression were significantly decreased in the muscle of diabetic mice by respectively 30 and 50% as compared to nondiabetic ec-Prkcd\(^{ff}\) animals (Figure 3(a) and (b)). However, mRNA expressions were not fully restored in diabetic ec-Prkcd\(^{-/-}\) mice as compared to diabetic ec-Prkcd\(^{ff}\) mice suggesting that PKC\(\delta\) in EC is not responsible for the expression of VEGF-A and PDGF-B in the muscle. Similarly, PDGFR-\(\beta\) mRNA expression was significantly blunted in diabetic ec-Prkcd\(^{ff}\) mice and remained decreased with the absence of PKC\(\delta\) in EC (Figure 3(c)). Interestingly, VEGFR2 mRNA was restored by 60% \((p = 0.0314)\) in diabetic ec-Prkcd\(^{-/-}\) mice as compared to diabetic ec-Prkcd\(^{ff}\) mice (Figure 3(d)). The expression of eNOS is essential for EC function and its
activity is regulated in part by VEGFR2. Our data demonstrated that diabetes reduced the mRNA expression of eNOS in the ischemic diabetic muscle, which was restored with the ablation of PKCδ specifically in EC (Figure 3(e)).

**VEGFR2 activation and signaling pathways are restored in diabetic endothelial-specific PKCδ null mice**

Since VEGFR2 expression was restored in diabetic ec-Prkcd<sup>fl/fl</sup> mice, we have investigated the downstream signaling pathways of VEGF in the ischemic muscle. Our results indicated that the activation of VEGFR2 was reduced in diabetic ec-Prkcd<sup>fl/fl</sup> animals and fully restored in diabetic ec-Prkcd<sup>−/−</sup> mice (Figure 4(a)). One of the downstream targets of VEGFR2 is the phosphorylation of Akt, which promotes cell survival. The activation of Akt was significantly reduced by 50% (p=0.0453) in the diabetic ischemic muscle of ec-Prkcd<sup>fl/fl</sup> mice and completely prevented with the ablation of PKCδ specifically in EC (Figure 4(a)). Activation of Akt leads to eNOS phosphorylation in EC. Similar to eNOS mRNA expression, eNOS phosphorylation was abrogated in the ischemic muscle of diabetic ec-Prkcd<sup>fl/fl</sup> mice and the endothelial-specific deletion of PKCδ maintained eNOS phosphorylation.

![Figure 3. Decreased mRNA expression of angiogenic factors and eNOS in the muscle of diabetic ec-Prkcd<sup>fl/fl</sup> mice.](image-url)
phosphorylation in the ischemic muscle (Figure 4(a)). PLC-γ, a downstream regulator of the VEGF pathway, exhibited a similar pattern as eNOS expression (Figure 4(b)). In contrast, Src activation was significantly ($p = 0.0049$) enhanced in the ischemic muscle of diabetic ec-Prkcd$^{ff}$ mice compared to nondiabetic ec-Prkcd$^{ff}$ mice. The ablation of PKCδ in EC led to a significant ($p = 0.0126$) reduction of Src phosphorylation in the ischemic muscle of diabetic ec-Prkcd$^{-/-}$ mice (Figure 4(b)).

SHP-1 expression and phosphatase activity were increased in the muscle of diabetic mice and abrogated with the inhibition of PKCδ

We have previously demonstrated that PKCδ activation was associated with increased SHP-1 expression in retinal pericytes$^{15}$ and renal epithelial cells of diabetic mice.$^{36}$ Our data demonstrated a significant 2.5-fold increase ($p = 0.0156$) of SHP-1 expression in the ischemic muscle of diabetic ec-Prkcd$^{ff}$ mice (Figure 4(c)). SHP-1 expression was reduced by 58% in the ischemic muscle of diabetic ec-Prkcd$^{-/-}$ mice as compared to diabetic ec-Prkcd$^{ff}$ mice but it was not statistically significant ($p = 0.2122$). Due to cell heterogeneity that compose the skeletal muscle, EC were extracted from the lungs of each group and then stimulated with VEGF-A. First, we confirmed ex vivo that the activation of Akt was twice as high in VEGF stimulated EC from nondiabetic ec-Prkcd$^{ff}$ mice as compared to non-stimulated cells ($p = 0.0172$) and blunted in EC from diabetic ec-Prkcd$^{ff}$ mice (Figure 5(a)). In contrast, the phosphorylation of Akt was enhanced in EC from diabetic ec-Prkcd$^{-/-}$ mice ($p < 0.0001$) as compared to diabetic ec-Prkcd$^{ff}$ mice following VEGF stimulation (Figure 5(a)). Since it has been shown that enhanced SHP-1 phosphatase activity, rather than expression, decreased VEGF.

Figure 4. Decreased activation of the VEGF signaling pathway and increased expression of SHP-1 in the muscle of diabetic ec-Prkcd$^{ff}$ mice: (a) expression of phospho-VEGFR (Y1175), VEGFR, phospho-eNOS (S1177), eNOS, phospho-Akt (S473), (b) phospho-PLC-γ (Y783), PLC-γ, phospho-Src (Y416), Src, and (c) SHP-1 and GAPDH in ischemic muscle of nondiabetic (NDM) and diabetic (DM) ec-Prkcd$^{ff}$ and ec-Prkcd$^{-/-}$ mice. Protein expression was detected by immunoblot blot, and densitometric quantitation was measured. Results are shown as mean ± SD of 8–10 mice per group.
signaling, we investigated if this increase could be dependent on PKCδ activation. Due to technical limitations involving an insufficient amount of lung ECs from mice, BAEC were infected with adenoviral vector containing the dominant negative form of PKCδ in phosphatase assay. Interestingly, SHP-1 phosphatase activity was significantly increased by 50% (p=0.0111) in BAEC exposed to HG levels as compared to NG, whereas the overexpression of the dominant negative form of PKCδ significantly prevented SHP-1 phosphatase activity in HG conditions (p=0.0019) (Figure 5(b)). The role of SHP-1 in PKCδ-induced VEGF inhibition was also explored. As expected, VEGF-stimulated BAECs exhibited a 4-fold increase in the activation of Akt as compared to non-stimulated cells (p<0.0001), an effect that was significantly decreased by 35% by HG level exposure (p=0.0303). Interestingly, the overexpression of the dominant negative form of SHP-1 in BAECs exposed to HG levels completely restored VEGF-induced phosphorylation of Akt (p=0.0035), an effect that was blunted in control GFP-overexpressed BAECs (Figure 5(c)).

**Discussion**

PAD is more frequent, aggressive and occurs younger in diabetic individuals, which causes worse outcomes and increases the risk of lower limb amputations. Although hyperglycemia is known to alter VEGF-induced angiogenic responses, the underlying molecular mechanisms of reduced VEGF expression and activity in diabetic PAD remain unclear. We have previously uncovered the involvement of the PKCδ isoform in the inhibition of VEGF signaling in the whole ischemic muscle of diabetic mice. In our current study, we demonstrated for the first time that hyperglycemia-induced activation of PKCδ specifically in EC reduced VEGFR2 activity and blood flow reperfusion following ischemia of a diabetic limb. Improved blood flow reperfusion observed in diabetic ec-Prkcd−/− mice was associated with increased density of small vessels (diameter <10 µm) and arterioles (<30 µm). Hyperglycemia has been shown to affect EC

---

**Figure 5.** Akt expression and activation in lung EC and SHP-1 phosphatase activity in BAEC. (a) expression of phospho-Akt (S473) and total Akt in EC isolated from the lungs of diabetic (DM) and non-diabetic (NDM) ec-Prkcdf/f and ec-Prkcd−/− mice exposed to NG (clear bars) or HG (black bars) concentrations followed by VEGF stimulation. Protein expression was detected by immunoblot blot, and densitometric quantitation was measured, (b) phosphatase activity of SHP-1 in BAEC infected or not with the adenoviral vector of dominant negative form of PKCδ, and (c) expression of phospho-Akt (S473), total Akt and SHP-1 in BAECs infected with either Ad-GFP or Ad-dnSHP-1 and exposed to NG (clear bars) or HG (black bars) concentrations followed by VEGF stimulation. Protein expression was detected by immunoblot blot, and densitometric quantitation was measured. Results are shown as mean ± SD test of 4 (a) and 5 (b, c) independent experiments.
proliferation, migration and tubule formation, three significant steps of the angiogenic process. Therefore, deletion of PKCδ in EC may promote angiogenesis by restoring EC function in a diabetic state. A shared factor of many diabetic vascular complications is the enhanced rate of cellular apoptosis. Therefore, impaired blood flow reperfusion could be due to early EC apoptosis during ischemia. Diabetes increased EC apoptosis in the ischemic muscle, which was reduced by the deletion of PKCδ specifically in EC.

Both VEGF-A and PDGF-B play a complementary role in the regulation of the angiogenic response to ischemia. VEGF is involved in the early steps of angiogenesis while PDGF is required for the maturation and stabilization of newly formed vessels. We observed a decrease in the gene expression of both VEGF-A and PDGF-B in the ischemic muscle of diabetic mice. These results were consistent with previous findings using rat and rabbit models. However, the expression of VEGF-A, PDFG-B, and PDGFR-β was not restored by the endothelial-specific deletion of PKCδ. Given that perivascular cells are also known to produce VEGF and PDGF, the endothelial-specific deletion of PKCδ could have been insufficient to compensate for decreased expression of pro-angiogenic factors in the whole adductor muscle. Likewise, as PDGFR-β is mainly expressed in vascular smooth muscle cells, the absence of PKCδ only in EC may not be sufficient to influence the PDGFR-β expression in the entire muscle tissue. However, this hypothesis will require further investigation.

The alteration of VEGFR2 activation is associated with an impaired angiogenic response. Previous studies have shown that high glucose levels reduced VEGFR2 expression and activation in primary EC and diabetic mice. Our data demonstrated that the endothelial-specific deletion of PKCδ preserved VEGFR2 phosphorylation. Akt and eNOS are key downstream effectors of the VEGF pathway that promote EC survival, permeability, and migration. Interestingly, activation of Akt and eNOS was recovered in the ischemic muscle of diabetic mice lacking PKCδ only in EC. Another study reported that the inhibition of PKCδ promoted metabolic activity and expansion of the hematopoietic stem and progenitor cells partially through the PI3K/Akt pathway. PKCδ-induced alteration of EC function in diabetes was corroborated by a similar Akt inhibition pattern observed in isolated EC from the lungs of diabetic cc-Prkcd−/− mice. The reestablishment of Akt activation in EC of diabetic cc-Prkcd−/− mice confirmed the involvement of PKCδ in diabetes-induced inhibition of the VEGF signaling pathway.

Protein tyrosine phosphatases are critical to downregulate cell response to growth factors by decreasing receptor tyrosine kinase phosphorylation. It has been reported that SHP-1 negatively regulated the VEGF pathway by inhibiting EC proliferation in vitro. The inhibition of SHP-1 increased VEGFR2 phosphorylation and enhanced capillary density in a nondiabetic ischemic rat model. Hyperglycemia-induced SHP-1 overexpression has been shown to interact with nephrin in podocytes and PDGFR in retinal pericytes leading to the progression of diabetic nephropathy and retinopathy, respectively. In the context of PAD, our data showed that SHP-1 expression was increased in the muscle of diabetic animals. The deletion of PKCδ specifically in EC did not significantly reduce SHP-1 expression suggesting that other cells might have contributed to the upregulation of SHP-1 in the entire muscle. On the other hand, increased phosphatase activity of SHP-1 in EC exposed to high glucose levels was abrogated by the overexpression of a dominant negative form of PKCδ. Our data suggest that PKCδ regulates SHP-1 activity rather than its expression. Furthermore, inhibition of SHP-1 restored VEGF-induced Akt activation in EC exposed to high glucose concentrations. While these results do not establish a direct connection between SHP-1 and PKCδ, it at least confirmed that SHP-1 is involved in impaired VEGF signaling actions caused by hyperglycemic condition in EC. Nevertheless, additional experiments will be required to determine if the effects of SHP-1 deletion are dependent of the activation of PKCδ in a diabetic EC. Another limitation of our study is that PKCδ is known to affect other important angiogenic pathways such as PDGF and angiotensin signaling. Therefore, the improvement of angiogenesis observed by the ablation of PKCδ in EC could also have been partially due to the reestablishment of the above-mentioned pro-angiogenic pathways.

In summary, our study provided new insights on diabetes-induced PKCδ activation specifically in EC, which was shown to contribute to the inhibition of VEGFR2 signaling through the increase in SHP-1 phosphatase activity. Our data enhance our knowledge of the molecular mechanisms underlying poor collateral vessel formation induced by diabetes and highlight PKCδ as a potential pharmacological target to treat PAD in diabetic patients. However, potential therapeutic modulation of PKCδ in patients with diabetes and PAD needs to be locally selective to EC in ischemic muscle as pathological events may arise from systemic treatment. Indeed, PKCδ isoformal form is involved in several cardiovascular diseases and systemic deletion of PKCδ has been shown to accelerate atherosclerotic lesions in mice and enhance the expression of connective tissue growth factor in cardiomyocytes leading to the progression of cardiac fibrosis in diabetic cardiomyopathy.

Acknowledgements

The authors gratefully acknowledge Anne Vezina (Department of Cell Anatomy, U. of Sherbrooke) for her assistance with the histology technics. Dr. Geraldes is the guarantor of this work, had full access to all the data, and takes full responsibility for the integrity of the data and the accuracy of data analysis.
Author contributions
L.C., C.M., E.F-C., A.N., S.R., V.B., and F.L. performed experiments. A.G. performed animal care and researched data. C.M., F.L. and P.G. analyzed the data and wrote the manuscript. M.-A. D. reviewed the manuscript and provided comments.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the Canadian Institute of Health Research [PTJ159627 to P.G.]. This work was performed at the CHUS research center, funded by the “Fonds de Recherche du Québec – Santé” (FRQ-S). Dr. Geraldes is currently the holder of the Canada Research Chair in Vascular Complications of Diabetes.

ORCID iDs
Étienne Fafard-Couture https://orcid.org/0000-0001-9789-4650
Pedro Geraldes https://orcid.org/0000-0002-2613-6710

Supplemental material
Supplemental material for this article is available online.

References
1. Dieter RS, Chu WW, Pacanowski JP, et al. The significance of lower extremity peripheral arterial disease. Clin Cardiol 2002; 25(1): 3–10.
2. American Diabetes Association. Peripheral arterial disease in people with diabetes. Clin Diabetes 2004; 22(4): 181–189.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9(6): 8.
4. Lamalice L, Le Boeuf F and Huot J. Endothelial Cell Migration During Angiogenesis. Circ Res 2007; 100(6): 782–794.
5. Takeshita S, Rossow ST, Kearney M, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147(6): 1649–1660.
6. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF 165 Gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102(9): 965–974.
7. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenosial delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108(16): 1933–1938.
8. Hazarika S, Dokun AO, Li Y, et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007; 101(9): 948–956.
9. Paquin-Veillette J, Lizzote F, Robillard S, et al. Deletion of AT2 receptor prevents SHP-1-induced VEGF inhibition and improves blood flow reperfusion in diabetic ischemic hindlimb. Arterioscler Thromb Vase Biol 2017; 37(12): 2291–2300.
10. Geraldes P and King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106(8): 1319–1331.
11. Durpès M-C, Morin C, Paquin-Veille J, et al. PKC-β activation inhibits IL-1β-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res 2015; 106(2): 303–313.
12. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of Cyclooxygenase-2 and alters prostanol profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003; 107(7): 1017–1023.
13. Lizzote F, Paré M, Denhez B, et al. PKCδ impaired vessel formation and angiogenic factor expression in diabetic ischemic limbs. Diabetes 2013; 62(8): 2948–2957.
14. Li Q, Park K, Xia Y, et al. Regulation of macrophage apoptosis and atherosclerosis by lipid-induced PKCδ isoform activation. Circ Res 2017; 121(10): 1153–1167.
15. Geraldes P, Hiraoka-Yamamoto M, Matsumoto M, et al. Activation of PKCδ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009; 15(11): 1298–1306.
16. Mima A, Kitada M, Geraldes P, et al. Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy. FASEB J 2012; 26(7): 2963–2974.
17. Otrock Z, Mahfouz R, Makarem J, et al. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007; 39(2): 212–220.
18. Gadad PC, Matthews KH and Knott RM. Role of HIF1α and PKCδ in mediating the effect of oxygen and glucose in a novel wound assay. Microvasc Res 2013; 88: 61–69.
19. Kolluru GK, Bir SC and Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; 2012: 1–30.
20. Varma S, Lal BK, Zheng R, et al. Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol-Heart Circ Physiol 2005; 289(4): H1744–H1751.
21. Lee C-H, Shieh Y-S, Hsiao F-C, et al. High glucose induces human endothelial dysfunction through an Axl-dependent mechanism. Cardiovasc Diabetol 2014; 13(1): 53.
22. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2(12): 1097–1105.
23. Andrae J, Gallini R and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22(10): 1276–1312.
24. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107(9): 1083–1092.
25. Sennino B, Kuhnert F, Tabruyn SP, et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009; 69(10): 4527–4536.
26. Raica M and Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGFR receptors (PDGFR) axis as target for anti-tumor and antiangiogenic therapy. *Pharmaceuticals* 2010; 3(3): 572–599.

27. Warren CM, Ziyad S, Briot A, et al. A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. *Sci Signal* 2014; 7(307): ral–ra1.

28. Somanath PR, Razorenova OV, Chen J, et al. Akt1 in endothelial cell and angiogenesis. *Cell Cycle* 2006; 5(5): 512–518.

29. Dimmeler S, Dernbach E and Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. *FEBS Lett* 2000; 477(3): 258–262.

30. Rao TN, Gupta MK, Softic S, et al. Attenuation of PKCδ enhances metabolic activity and promotes expansion of blood progenitors. *EMBO J* 2018; 37(24): e100409.

31. Hale AJ, ter Steege E and den Hertog J. Recent advances in understanding the role of protein-tyrosine phosphatases in development and disease. *Dev Biol* 2017; 428(2): 283–292.

32. Bhattacharya R, Kwon J, Wang E, et al. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF receptor-2 and attenuates endothelial DNA synthesis, but not migration. *J Mol Signal* 2008; 3: 8.

33. Sugano M, Tsuchida K, Maeda T, et al. SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia. *Atherosclerosis* 2007; 191(1): 33–39.

34. Denhez B, Lizotte F, Guimond M-O, et al. Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes. *J Biol Chem* 2015; 290(1): 350–358.

35. Leitges M, Mayr M, Braun U, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cδ-null mice. *J Clin Invest* 2001; 108(10): 1505–1512.

36. He Z, Way KJ, Arikawa E, et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium. *J Biol Chem* 2005; 280(16): 15719–15726.

37. Chintalgattu V and Katwa LC. Role of protein kinase C-δ in angiotensin II induced cardiac fibrosis. *Biochem Biophys Res Commun* 2009; 386(4): 612–616.